These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24867420)

  • 1. The acoustic features of inhalation can be used to quantify aerosol delivery from a Diskus™ dry powder inhaler.
    Seheult JN; O'Connell P; Tee KC; Bholah T; Al Bannai H; Sulaiman I; MacHale E; D'Arcy S; Holmes MS; Bergin D; Reeves E; Reilly RB; Crispino-O'Connell G; Ehrhardt C; Healy AM; Costello RW
    Pharm Res; 2014 Oct; 31(10):2735-47. PubMed ID: 24867420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the relationship between peak inspiratory flow rate and volume of inhalation from a Diskus™ Inhaler and baseline spirometric parameters: a cross-sectional study.
    Seheult JN; Costello S; Tee KC; Bholah T; Al Bannai H; Sulaiman I; Costello RW
    Springerplus; 2014; 3():496. PubMed ID: 25279290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Acoustic-Based Method to Detect and Quantify the Effect of Exhalation into a Dry Powder Inhaler.
    Holmes MS; Seheult JN; O'Connell P; D'Arcy S; Ehrhardt C; Healy AM; Costello RW; Reilly RB
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):247-53. PubMed ID: 25393346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring Inhaler Inhalations Using an Acoustic Sensor Proximal to Inhaler Devices.
    Taylor TE; Holmes MS; Sulaiman I; Costello RW; Reilly RB
    J Aerosol Med Pulm Drug Deliv; 2016 Oct; 29(5):439-446. PubMed ID: 26859629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Common Inhaler Errors on Drug Delivery: Investigating Critical Errors with a Dry Powder Inhaler.
    Sulaiman I; Seheult J; Sadasivuni N; MacHale E; Killane I; Giannoutsos S; Cushen B; Mokoka MC; Bhreathnach AS; Boland F; Reilly RB; Costello RW
    J Aerosol Med Pulm Drug Deliv; 2017 Aug; 30(4):247-255. PubMed ID: 28277810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder.
    Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK
    Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method of estimating inspiratory flow rate and volume from an inhaler using acoustic measurements.
    Holmes MS; Seheult JN; Geraghty C; D'Arcy S; O'Brien U; Crispino O'Connell G; Costello RW; Reilly RB
    Physiol Meas; 2013 Aug; 34(8):903-14. PubMed ID: 23892977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
    Mahler DA; Waterman LA; Ward J; Gifford AH
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Airway Epithelial Lining Fluid and Plasma Pharmacokinetics of Inhaled Fluticasone Propionate and Salmeterol Xinafoate in Mechanically Ventilated Pigs.
    Ewing P; Oag S; Lundqvist A; Stomilovic S; Stellert I; Antonsson M; Nunes SF; Andersson PU; Tehler U; Sjöberg C; Péterffy A; Gerde P
    J Aerosol Med Pulm Drug Deliv; 2021 Aug; 34(4):231-241. PubMed ID: 33216656
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
    Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics.
    Tarsin WY; Pearson SB; Assi KH; Chrystyn H
    Int J Pharm; 2006 Jun; 316(1-2):131-7. PubMed ID: 16584855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Delivered by the Diskustrade mark or Pressurised Metered-Dose Inhaler in Children with Asthma.
    Bracamonte T; Schauer U; Emeryk A; Godwood A; Balsara S
    Clin Drug Investig; 2005; 25(1):1-11. PubMed ID: 17523742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.
    Ghosh S; Ohar JA; Drummond MB
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):381-387. PubMed ID: 28933581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of dry powder aerosolization mechanisms in different channel designs.
    Chen L; Heng RL; Delele MA; Cai J; Du DZ; Opara UL
    Int J Pharm; 2013 Nov; 457(1):143-9. PubMed ID: 24055441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer.
    Clearie KL; Williamson PA; Vaidyanathan S; Du Bois J; Nell H; Lipworth BJ
    Br J Clin Pharmacol; 2010 Jun; 69(6):637-44. PubMed ID: 20565455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.